Gut microbiota and its metabolites in depression: from pathogenesis to treatment

Major depressive disorder is one of the most disabling mental disorders worldwide. Increasing preclinical and clinical studies have highlighted that compositional and functional (e.g., metabolite) changes in gut microbiota, known as dysbiosis, are associated with the onset and progression of depress...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:EBioMedicine Ročník 90; s. 104527
Hlavní autoři: Liu, Lanxiang, Wang, Haiyang, Chen, Xueyi, Zhang, Yangdong, Zhang, Hanping, Xie, Peng
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier B.V 01.04.2023
Elsevier
Témata:
Advanced Basic Science
Depression
Depression - etiology
Depression - therapy
Depressive Disorder, Major - complications
Depressive Disorder, Major - therapy
Dysbiosis - therapy
Fecal Microbiota Transplantation
Gastrointestinal Microbiome
Gut microbiota
Humans
Internal Medicine
Metabolites
Microbial-targeted therapeutics
Pathogenesis
Probiotics - therapeutic use
Review
Gut microbiota
Depression
Metabolites
Microbial-targeted therapeutics
Pathogenesis
ISSN:2352-3964, 2352-3964
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Major depressive disorder is one of the most disabling mental disorders worldwide. Increasing preclinical and clinical studies have highlighted that compositional and functional (e.g., metabolite) changes in gut microbiota, known as dysbiosis, are associated with the onset and progression of depression via regulating the gut-brain axis. However, the gut microbiota and their metabolites present a double-edged sword in depression. Dysbiosis is involved in the pathogenesis of depression while, at the same time, offering a novel therapeutic target. In this review, we describe the association between dysbiosis and depression, drug–microbiota interactions in antidepressant treatment, and the potential health benefits of microbial-targeted therapeutics in depression, including dietary interventions, fecal microbiota transplantation, probiotics, prebiotics, synbiotics, and postbiotics. With the emergence of microbial research, we describe a new direction for future research and clinical treatment of depression.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
These authors contributed equally to this work.
ISSN:2352-3964
2352-3964
DOI:10.1016/j.ebiom.2023.104527